Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid levels in women with comorbid depression and panic disorder

International Journal of Neuropsychopharmacology

Volumn 9, Issue 5, 2006, Pages 547-556

  Sullivan, Gregory M ^a   Oquendo, Maria A ^a   Huang, Yung Yu ^a   Mann, J John ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

5 hydroxylindoleacetic acid (5 HIAA); Anxiety; Comorbidity; Major depression; Panic disorder; Serotonin

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; MONOAMINE; NORADRENALIN; SEROTONIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUMBAR PUNCTURE; MAJOR DEPRESSION; MENTAL PATIENT; PANIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SEROTONIN METABOLISM; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

ADULT; ANALYSIS OF VARIANCE; DEPRESSION; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; MIDDLE AGED; PANIC DISORDER; SPINAL PUNCTURE;

EID: 33750208252     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006231     Document Type: Article

References (67)

1. Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ (1986). Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. Journal of Psychiatric Research 20, 175-193.
2. Anderson GM, Bennett AJ, Weld KP, Pushkas JG, Ocame DM, Higley JD (2002). Serotonin in cisternal cerebrospinal fluid of rhesus monkeys: basal levels and effects of sertraline administration. Psychopharmacology (Berlin) 161, 95-99.
3. Andrade L, Eaton WW, Chilcoat H (1994). Lifetime comorbidity of panic attacks and major depression in a population-based study. Symptom profiles. British Journal of Psychiatry 165, 363-369.
4. Andrews G, Slade T, Issakidis C (2002). Deconstructing current comorbidity: data from the Australian National Survey of Mental Health and Well-Being. British Journal of Psychiatry 181, 306-314.
5. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Press.
6. Asberg M (1997). Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Annals of the New York Academy of Science 836, 158-181.
7. 3H]imipramine binding. Ciba Foundation Symposium 123, 57-83.
8. Banki CM (1981). Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. Journal of Neural Transmission 50, 89-101.
9. Banki CM, Molnar G (1981a). Cerebrospinal fluid 5-hydroxyindoleacetic acid as an index of central serotonergic processes. Psychiatry Research 5, 23-32.
10. Banki CM, Molnar G (1981b). The influence of age, height, and body weight on cerebrospinal fluid amine metabolites and tryptophan in women. Biological Psychiatry 16, 753-762.
11. Beck AT, Beck R, Kovacs M (1975). Classification of suicidal behaviors: I. Quantifying intent and medical lethality. American Journal of Psychiatry 132, 285-287.
12. Beck AT, Kovacs M, Weissman A (1979). Assessment of suicidal intention: the Scale for Suicide Ideation. Journal of Consulting and Clinical Psychology 47, 343-352.
13. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Archives of General Psychiatry 4, 561-571.
14. Bennett AJ, Lesch KP, Heils A, Long JC, Lorenz JG, Shoaf SE, Champoux M, Suomi SJ, Linnoila MV, Higley JD (2002). Early experience and serotonin transporter gene variation interact to influence primate CNS function. Molecular Psychiatry 7, 118-122.
15. Bjerkenstedt L, Edman G, Flyckt L, Hagenfeldt L, Sedvall G, Wiesel FA (1985). Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor - a dose-response study in depressed patients. Psychopharmacology (Berlin) 87, 253-259.
16. Blennow K, Wallin A, Gottfries CG, Karlsson I, Mansson JE, Skoog I, Wikkelso C, Svennerholm L (1993). Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. European Neuropsychopharmacol 3, 55-61.
17. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF (1979). Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Research 1, 131-139.
18. Carpenter LL, Anderson GM, Siniscalchi JM, Chappell PB, Price LH (2003). Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28, 339-347.
19. Clayton PJ (1990). The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. Journal of Clinical Psychiatry 51 (Suppl.), 35-39.
20. Clayton PJ, Grove WM, Coryell W, Keller M, Hirschfeld R, Fawcett J (1991). Follow-up and family study of anxious depression. American Journal of Psychiatry 148, 1512-1517.
21. Coryell W, Endicott J, Andreasen NC, Keller MB, Clayton PJ, Hirschfeld RM, Scheftner WA, Winokur G (1988). Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. American Journal of Psychiatry 145, 293-300.
22. Coryell W, Endicott J, Winokur G (1992). Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. American Journal of Psychiatry 149, 100-107.
23. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33, 766-771.
24. Eriksson E, Westberg P, Alling C, Thuresson K, Modigh K (1991). Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Research 36, 243-251.
25. Esler M, Alvarenga M, Lambert G, Kaye D, Hastings J, Jennings G, Morris M, Schwarz R, Richards J (2004). Cardiac sympathetic nerve biology and brain monoamine turnover in panic disorder. Annals of the New York Academy of Sciences 1018, 505-514.
26. Fawcett J (1992). Suicide risk factors in depressive disorders and in panic disorder. Journal of Clinical Psychiatry 53 (Suppl.), 9-13.
27. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, Gibbons R (1990). Time-related predictors of suicide in major affective disorder. American Journal of Psychiatry 147, 1189-1194.
28. Feske U, Frank E, Kupfer DJ, Shear MK, Weaver E (1998). Anxiety as a predictor of response to interpersonal psychotherapy for recurrent major depression: an exploratory investigation. Depression & Anxiety 8, 135-141.
29. First M, Spitzer R, Gibbon M, Williams J (1995). Structured Clinical Interview for DSM-IV Axis I Disorders (SCIP-I/P), Version 2.0. New York: Biometrics Research Group, New York State Psychiatric Institute.
30. George DT, Adinoff B, Ravitz B, Nutt DJ, De Jong J, Berrettini W, Mefford IN, Costa E, Linnoila M (1990). A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism. Acta Psychiatrica Scandinavica 82, 1-7.
31. Grunhaus L, Harel Y, Krugler T, Pande AC, Haskett RF (1988). Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications. Clinical Neuropharmacology 11, 454-461.
32. Grunhaus L, Pande AC, Brown MB, Greden JF (1994). Clinical characteristics of patients with concurrent major depressive disorder and panic disorder. American Journal of Psychiatry 151, 541-546.
33. Grunhaus L, Rabin D, Greden JF (1986). Simultaneous panic and depressive disorder: response to antidepressant treatments. Journal of Clinical Psychiatry 47, 4-7.
34. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23, 56-62.
35. Hirschfeld RM (2000). History and evolution of the monoamine hypothesis of depression. Journal of Clinical Psychiatry 61 (Suppl. 6), 4-6.
36. Johansson F, von Knorring L, Sedvall G, Terenius L (1980). Changes in endorphins and 5-hydroxyindoleacetic acid in cerebrospinal fluid as a result of treatment with a serotonin reuptake inhibitor (zimelidine) in chronic pain patients. Psychiatry Research 2, 167-172.
37. Johnson J, Weissman MM, Klerman GL (1990). Panic disorder, comorbidity, and suicide attempts. Archives of General Psychiatry 47, 805-808.
38. Johnson MR, Lydiard RB (1998). Comorbidity of major depression and panic disorder. Journal of Clinical Psychology 54, 201-210.
39. Jonsson EG, Bah J, Melke J, Abou Jamra R, Schumacher J, Westberg L, Ivo R, Cichon S, Propping P, Nothen MM, Eriksson E, Sedvall GC (2004). Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry 4, 4.
40. Katon W, Roy-Byrne PP (1991). Mixed anxiety and depression. Journal of Abnormal Psychology 100, 337-345.
41. Kent JM, Mathew SJ, Gorman JM (2002). Molecular targets in the treatment of anxiety. Biological Psychiatry 52, 1008-1030.
42. Kupfer DJ, Charney DS (2003). 'Difficult-to-treat depression'. Biological Psychiatry 53, 633-634.
43. Leckman JF, Merikangas KR, Pauls DL, Prusoff BA, Weissman MM (1983a). Anxiety disorders and depression: contradictions between family study data and DSM-III conventions. American Journal of Psychiatry 140, 880-882.
44. Leckman JF, Weissman MM, Merikangas KR, Pauls DL, Prusoff BA (1983b). Panic disorder and major depression. Increased risk of depression, alcoholism, panic, and phobic disorders in families of depressed probands with panic disorder. Archives of General Psychiatry 40, 1055-1060.
45. Lepine JP (2001). Epidemiology, burden, and disability in depression and anxiety. Journal of Clinical Psychiatry 62 (Suppl. 13), 4-10 (discussion, 11-12).
46. Lepola U, Jolkkonen J, Pitkanen A, Riekkinen P, Rimon R (1990). Cerebrospinal fluid monoamine metabolites and neuropeptides in patients with panic disorder. Annals of Medicine 22, 237-239.
47. Lundmark J, Walinder J, Alling C, Manniche PM, Dalgaard L (1994). The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. European Neuropsychopharmacol 4, 1-6.
48. Merikangas KR, Angst J, Eaton W, Canino G, Rubio-Stipec M, Wacker H, Wittchen HU, Andrade L, Essau C, Whitaker A, Kraemer H, Robins LN, Kupfer DJ (1996). Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. British Journal of Psychiatry (Suppl.), 58-67.
49. Moir AT, Ashcroft GW, Crawford TB, Eccleston D, Guldberg HC (1970). Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 93, 357-368.
50. Ninan PT, Berger J (2001). Symptomatic and syndromal anxiety and depression. Depression & Anxiety 14, 79-85.
51. Oquendo MA, Halberstam B, Mann JJ (2003). Risk factors for suicidal behavior: utility and limitations of research instuments. In First MB (Ed.), Standardized Evaluation in Clinical Practice. Washington, DC: American Psychiatric Publishing, Inc.
52. Paykel ES (1994). Historical overview of outcome of depression. British Journal of Psychiatry (Suppl.), 6-8.
53. Placidi GP, Oquendo MA, Malone KM, Brodsky B, Ellis SP, Mann JJ (2000). Anxiety in major depression: relationship to suicide attempts. American Journal of Psychiatry 157, 1614-1618.
54. Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ (2001). Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biological Psychiatry 50, 783-791.
55. Pohl R, Yeragani VK, Balon R, Lycaki H (1988). The jitteriness syndrome in panic disorder patients treated with antidepressants. Journal of Clinical Psychiatry 49, 100-104.
56. Roy-Byrne P, Stein M, Bystrisky A, Katon W (1998). Pharmacotherapy of panic disorder: proposed guidelines for the family physician. Journal of the American Board of Family Practice 11, 282-290.
57. Scheinin M, Chang WH, Kirk KL, Linnoila M (1983). Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. Analytical Biochemistry 131, 246-253.
58. Sheline Y, Bardgett ME, Csernansky JG (1997). Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology 17, 11-14.
59. Sher L, Oquendo MA, Li S, Huang YY, Grunebaum MF, Burke AK, Malone KM, Mann JJ (2003). Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism. Neuropsychopharmacology 28, 1712-1719.
60. Spitzer RL, Williams JBW, Gibbon M, First MB (1990). Structured Clinical Interview for DSM-III-R Axis II Disorders (SCID-II). Washington, DC: American Psychiatric Press, Inc.
61. Stanley M, Traskman-Bendz L, Dorovini-Zis K (1985). Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sciences 37, 1279-1286.
62. Sullivan GM, Coplan JD, Kent JM, Gorman JM (1999). The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biological Psychiatry 46, 1205-1218.
63. VanValkenburg C, Akiskal HS, Puzantian V, Rosenthal T (1984). Anxious depressions. Clinical, family history, and naturalistic outcome-comparisons with panic and major depressive disorders. Journal of Affective Disorders 6, 67-82.
64. Warshaw MG, Dolan RT, Keller MB (2000). Suicidal behavior in patients with current or past panic disorder: five years of prospective data from the Harvard/Brown Anxiety Research Program. American Journal of Psychiatry 157, 1876-1878.
65. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ, Kuhn CM, Lewis JG, Schanberg SM, Stafford-Smith M, et al. (2003). Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology 28, 533-541.
66. Wittchen HU, Essau CA, Krieg JC (1991). Anxiety disorders: similarities and differences of comorbidity in treated and untreated groups. British Journal of Psychiatry (Suppl.), 23-33.
67. Zung WW, Magruder-Habib K, Velez R, Alling W (1990). The comorbidity of anxiety and depression in general medical patients: a longitudinal study. Journal of Clinical Psychiatry 51 (Suppl.), 77-80 (discussion, 81).